1, obesity: too much fat will supplement the storage of estrogen, and supplement the conversion of androstenedione into estrone in plasma. This free androstendione supplement with active estrogen may be a cancer triggering factor, or cancer promoting factor, for endometrial cancer. 2.Diabetes: diabetic patients or those with abnormal sugar tolerance have 2.8 times more risk of endometrial cancer than normal people. 3.High blood pressure: There are more endometrial cancer patients with high blood pressure. Obesity, diabetes and hypertension coexist in patients with endometrial cancer tumor, which is called “endometrial triad” or “endometrial cancer reunion”. The three may be related to high-fat tumor diet, which is directly related to endometrial cancer. 4.Menstrual disorders: Patients with endometrial cancer tumor have 3 times more menstrual disorders and high volume than normal women. Early menarche and late menarche: the rate of endometrial cancer is 60% higher for those who have menarche before 12 years old than those who have menarche after 12 years old. The age of endometrial cancer is 6 years later than that of normal women. 6. Pregnancy and childbirth: endometrial cancer is more common in those with multiple births, unborn children and infertility. 7.Polycystic ovarian regression: the clinical diagnosis manifests as non-ovulation, while the endometrium is under the effect of high and continuous estrogen, lack of progesterone regulation and periodic endometrial exfoliation, and produces proliferative changes. 8.Ovarian tumor: granuloma cell carcinoma and follicular membrane carcinoma cell carcinoma that secrete higher degree of estrogen can cause irregular menstruation, postmenstrual bleeding and endometrial hyperplasia and endometrial cancer. 9.Unusual hyperplasia of endometrium: it can be a stage of endometrial cancer development or no such stage. And severe atypical hyperplasia can be regarded as endometrial carcinoma in situ. 10.Exogenous estrogen: Women taking estrogen have a high risk of endometrial cancer, and the risk is related to the dose size, duration of taking, whether progestin is applied or not, whether the drug is stopped in the middle, and the patient’s special symptoms. The risk decreases in gray after discontinuation, but the risk persists for several years. The causal relationship between estrogen and endometrial cancer is now well documented.